Table 4.
Acquired AMR genes and fluoroquinolone resistance mutations identified in ESBL-Ec strains isolated from soldiers in June and November
| Combinations of resistance determinants | June, n = 17 n (%) |
November, n = 70 n (%) |
Total, n (%) |
|---|---|---|---|
| β-lactams | 17 (100.0) | 70 (100.0) | 87 (100.0) |
| blaCTX-M-15 & blaTEM-1 / blaCTX-M-15 & blaTEM-35 | 11 (64.7) | 32 (45.7)/2 (2.9) | 45 (51.7) |
| blaCTX-M-15 / blaCTX-M-1 | 2 (11.8)/1 (5.9) | 22 (31.4) | 25 (28.7) |
| blaCTX-M-15 & blaDHA-1 / +blaTEM-1 | 4 (5.7)/1 (1.4) | 5 (5.7) | |
| blaCTX-M-15 & blaOXA-1 / +blaTEM-1 | 1 (5.9) | 1 (1.4)/4 (5.7) | 6 (6.9) |
| blaCTX-M-27 | 1 (1.4) | 1 (1.1) | |
| blaCTX-M-27 & blaTEM-1 | 2 (11.8) | 2 (2.3) | |
| blaCTX-M-231 & blaTEM-1 | 3 (4.3) | 3 (3.4) | |
| Aminoglycosides | 14 (82.4) | 51 (72.9) | 65 (74.7) |
| aph(6)-Id & aph(3″)-Ib & aac(3)-IId & aadA5 or aadA2 | 4 (5.7) | 4 (4.6) | |
| aph(6)-Id & aph(3″)-Ib & aadA5 or aadA1 or aadA2 | 3 (17.6) | 9 (12.9) | 12 (13.8) |
| aph(6)-Id & aph(3″)-Ib & sat2 / sat2 | 3 (4.3)/2 (2.9) | 5 (5.7) | |
| aph(6)-Id & aph(3″)-Ib | 8 (47.1) | 12 (17.1) | 20 (23.0) |
| aadA5/aadA1 or aadA2 | 2 (11.8)/1 (5.9) | 11 (15.7)/10 (14.3) | 24 (27.6) |
| Aminoglycosides and quinolones | 1 (5.9) | 6 (8.6) | 7 (8.0) |
| aac(6′)-Ib-cr (D181Y) & aadA5 & aph(6)-Id & aph(3″)-Ib & aac(3)-IId | 2 (2.9) | 2 (2.3) | |
| aac(6′)-Ib-cr (D181Y) & aadA5 & aph(6)-Id & aph(3″)-Ib & aac(3)-IIe | 1 (5.9) | 1 (1.4) | 2 (2.3) |
| aac(6′)-Ib-cr (D181Y) & aadA5 / +aac(3)-IIe | 2 (2.9)/1 (1.4) | 3 (3.4) | |
| Quinolones | 14 (82.4) | 48 (68.6) | 62 (71.3) |
| qnrS1/qnrS1 & qnrB4 | 14 (82.4)/0 | 41 (58.6)/5 (7.1) | 60 (69.0) |
| qepA4 | 2 (2.9) | 2 (2.3) | |
| Trimethoprim/sulfonamides | 15 (88.2) | 64 (91.4) | 79 (90.8) |
| dfrA & sul | 15 (88.2) | 56 (80.0) | 71 (81.6) |
| dfrA/sul | 3 (4.3)/5 (7.1) | 8 (9.2) | |
| Tetracyclines | 15 (88.2) | 43 (61.4) | 58 (66.7) |
| tet(A)/tet(B) | 12 (70.6)/3 (17.6) | 26 (37.1)/16 (22.9) | 57 (65.5) |
| tet(A) & tet(B) | 1 (1.4) | 1 (1.1) | |
| Other | 6 (35.3) | 52 (74.3) | 58 (66.7) |
| mph(A) | 5 (29.4) | 41 (58.6) | 46 (52.9) |
| erm(B)/catA1 | 6 (8.6)/4 (5.7) | 10 (11.5) | |
| cmlA1 | 1 (5.9) | 1 (1.1) | |
| ere(A) | 1 (1.4) | 1 (1.1) | |
| gyrA and/or parC/E mutations | 5 (29.4) | 33 (47.1) | 38 (43.7) |
| gyrA(S83A) | 1 (5.9) | 1 (1.4) | 2 (2.3) |
| gyrA(S83L)/gyrA(S83L) & parC(S80I) | 13 (18.6)/2 (2.9) | 15 (17.2) | |
| gyrA(S83L) & gyrA(D87N) & parC(S80I or E84K) & parE(L416F) | 4 (23.5) | 1 (1.4) | 5 (5.7) |
| gyrA(S83L) & gyrA(D87N) & parC(S80I) & parE(I464F) | 1 (1.4) | 1 (1.1) | |
| gyrA(S83L) & gyrA(D87N) & parC(S80I) & parC(E84V) & parE(I529L) | 7 (10.0) | 7 (8.0) | |
| gyrA(S83L) & gyrA(D87N) & parC(S80I) & parE(S458A)/+parE(S458T) | 3 (4.3)/1 (1.4) | 4 (4.6) | |
| gyrA(S83L) & gyrA(D87N) & parC(S80I) & parE(S458T) | 1 (1.4) | 1 (1.1) | |
| gyrA(S83L) & parE(I355T or I529L) | 2 (2.9) | 2 (2.3) | |
| gyrA(S83V) & parC(p.S80I) | 1 (1.4) | 1 (1.1) |